Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 10, 2014; 5(4): 646-659
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.646
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.646
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer
Kazuhiro Asami, Shinji Atagi, Department of Clinical Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai City, Osaka 591-8555, Japan
Author contributions: Asami K and Atagi S both contributed to this paper.
Correspondence to: Kazuhiro Asami, MD, Department of Clinical Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, 1180 Nagasone-cho Kita-ku, Sakai City, Osaka 591-8555, Japan. kazu.taizo@nifty.com
Telephone: +81-72-2523021 Fax: +81-72-2511372
Received: December 22, 2013
Revised: April 22, 2014
Accepted: May 15, 2014
Published online: October 10, 2014
Revised: April 22, 2014
Accepted: May 15, 2014
Published online: October 10, 2014
Core Tip
Core tip: Although gefitinib and erlotinib provide a significant response and survival benefit, all responders eventually acquire resistance. Second-generation epidermal growth factor receptor (EGFR)-targeting agents, such as afatinib and dacomitinib, may improve survival further and be useful for patients who acquired resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). This review discusses novel therapeutic strategies for EGFR-mutated advanced non-small cell lung cancer using first- and second-generation EGFR-TKIs.